Mifepristone

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Weight-Gain Prevention

Conditions

Weight-Gain Prevention

Trial Timeline

Mar 1, 2007 → Jul 1, 2007

NCT ID

NCT00455442

About Mifepristone

Mifepristone is a phase 2 stage product being developed by Eli Lilly for Weight-Gain Prevention. The current trial status is completed. This product is registered under clinical trial identifier NCT00455442. Target conditions include Weight-Gain Prevention.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00455442	Phase 2	Completed	Mar 1, 2007	Jul 1, 2007	Weight-Gain Prevention